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Research
According to several epidemiologic studies,
chemical intolerance is a common problem
(Baldwin et al. 1997; Bell et al. 1993; Caress
and Steinemann 2003; Meggs et al. 1996),
with various kinds of elicited symptoms.
Nevertheless, the pathophysiology behind the
symptoms is unknown. A comprehensive term
for chemical intolerance is “multiple chemical
sensitivity” (MCS), which is associated with
symptoms in more than one organ after the
sufferer has been exposed to very low concen-
trations of chemical substances (Cullen 1987).
Because no objective investigations have, until
now, conﬁrmed a diagnosis of MCS, the dis-
order has been rejected as an established
organic disease (American Academy of Allergy
1999; Gots 1995; Staudenmayer 2001).
A subgroup of patients with airway com-
plaints, reporting cough and other airway
symptoms from scents and chemicals, had
an increased capsaicin cough sensitivity
(Millqvist et al. 1998; Ternesten-Hasseus
et al. 2002b). This capsaicin-induced cough
could be blocked by inhaled anesthesia, and it
was suggested that sensory nerves are involved
in the pathophysiology (Millqvist 2000).
Furthermore, elevated levels of sensory nerve-
mediated tachykinin substance P were found
in nasal lavage fluid (NAL) of patients with
chronic cough and increased capsaicin cough
sensitivity (Cho et al. 2003). Consequently,
we previously proposed a mechanism of
increased sensitivity of the afferent nerves in
patients with airway symptoms induced by
scents and chemicals and suggested using the
term “sensory hyperreactivity” (SHR; Millqvist
et al. 1998). 
Capsaicin, the ingredient that produces the
heat in hot chiles, is a well-known cough-
inducing agent when inhaled (Fuller et al.
1985; Karlsson et al. 1988; Midgren et al.
1992). Capsaicin stimulates unmyelinated,
afferent sensory C-ﬁbers. The capsaicin recep-
tor, vanilloid receptor 1 (VR1), has been iden-
tified (Caterina et al. 1997). This receptor
responds not only to capsaicin but may also
participate in the detection of noxious thermal
and chemical stimuli in vivo (Caterina et al.
1999; Tominaga and Julius 2000). In the skin,
VR1 is essential to selective modalities of pain
sensation and to tissue injury-induced thermal
hyperalgesia (Caterina et al. 2000). There is
also a link between pain and hyperalgesia, on
the one hand, and neurotrophins and cap-
saicin, on the other (Anand 1995, 2004; Shu
and Mendell 199b, 2001). Increased levels of
serum nerve growth factor (NGF) have been
reported in patients with MCS, and the levels
rose 1.5-fold after provocation with irritating
fumes (Kimata 2004). 
Neurotrophins are a group of four similar
proteins, which are essential for survival and
axonal outgrowth and development of sensory
neurons, including capsaicin-sensitive fibers
(Chun and Patterson 1977; Levi-Montalcini
1987; Lewin and Barde 1996; Shu and
Mendell 1999a, 2001). In the airways, the
most important neurotrophin is believed to be
NGF, but because it is derived primarily from
nonneuronal sources, its role in patients with
SHR is uncertain. Hypothesizing that a
neurochemical alteration takes place in
patients with SHR, we measured NGF levels
in nasal secretions before and after capsaicin
inhalation provocations and related the levels
to capsaicin cough sensitivity.
Materials and Methods
The study included 13 nonsmoking patients,
8 women and 5 men, 30–63 years of age (aver-
age age 50 years). They were referred to an
asthma and allergy outpatient clinic because of
symptoms suggestive of asthma or allergy, but,
during the workup, this could not be veriﬁed.
All participants had normal lung function
[forced expiratory volume during 1 sec (FEV1)
> 75% of predicted values], negative meta-
choline tests, and negative skin-prick tests
(using a standard panel of 11 allergens). None
demonstrated spirometric reversibility or vari-
ability in pulmonary function. Five patients
regularly used β2-agonists and/or inhalation
corticosteroids, but with no tangible effect. All
patients had tried β2-agonists and inhalation
corticosteroids, but 8 had stopped taking
medication completely because of its lack of
effect. None had a history of gastroesophageal
reﬂux or heart disease. 
The patients were screened using a ques-
tionnaire on airway symptoms and on symp-
toms in response to scents and chemicals. All
had a history of at least 2 years of coughing and
pronounced upper and lower airway symp-
toms induced by scents and chemicals. The
patients had positive reactions to a capsaicin
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Patients complaining of upper and lower airway symptoms caused by scents and chemicals have
previously been shown to have increased cough sensitivity to inhaled capsaicin, but the precise
mechanisms behind this reaction are unknown. Hypothesizing that a neurochemical alteration
related to sensory hyperreactivity (SHR) of the airway mucosa occurs, we measured levels of nerve
growth factor (NGF) in nasal lavage fluid (NAL) before and after capsaicin inhalation provoca-
tions and related the capsaicin cough sensitivity to the NGF levels. Thirteen patients with SHR
and 14 control subjects were provoked with capsaicin inhalation at three different doses. We
measured NGF in NAL before and after provocation and recorded cough and capsaicin-induced
symptoms. All subjects demonstrated a dose-dependent cough response to capsaicin inhalation,
with a more pronounced effect in patients than in controls. Basal levels of NGF were signiﬁcantly
lower in the patient group than in the control subjects (p < 0.01). After capsaicin provocation, the
patients showed a significant increase in NGF (p < 0.01), which was related to capsaicin cough
sensitivity. The findings demonstrate that, in patients with airway symptoms induced by scents
and chemicals, SHR is real and measurable, demonstrating a pathophysiology in the airways of
these patients compared to healthy subjects. Key words: airway symptoms, chemical intolerance,
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method described by Johansson et al. (2002).
They were diagnosed as having SHR as an
explanation for their airway symptoms, in
accordance with the guiding principles in this
article, which recommend this diagnosis for
patients with a combination of pronounced
airway sensitivity to chemicals and increased
capsaicin cough sensitivity. 
The control group consisted of 14 healthy,
nonsmoking subjects 29–69 years of age (aver-
age age 50 years), composed of 10 women and
4 men. None had a history of respiratory difﬁ-
culties, asthma, or allergy (except for 1 person
with an isolated positive reaction to birch), and
none was on regular medication. Informed con-
sent was obtained from all subjects at the start
of the investigation, which was approved by the
Hospital Ethics Committee in Gothenburg,
Sweden.
We performed capsaicin inhalation provo-
cation in accordance with previous studies
(Millqvist et al. 1998; Ternesten-Hasseus et al.
2002b). One milliliter of saline was nebulized
(Pariboy 36; Paulritzau Pari-Werk, Starnberg-
am-See, Germany) and inhaled to completion
over 6 min to induce coughing, followed by
4 min rest. The patients did not use a nose
clip during the provocations. We counted the
number of coughs for 10 min from the onset
of provocation and recorded them on tape.
Thereafter, we carried out provocations in the
same way, using increasing concentrations of
capsaicin: 0.4, 2, and 10 µM in a 1-ml solu-
tion. We measured FEV1 with a spirometer
(Vitalograph, Buckingham, UK) before and
after each provocation and recorded the best
of two trials. Following each provocation, we
registered symptoms by scoring them on a
scale of 0–3 (0 = no symptoms, and 1 = mild,
2 = moderate, and 3 = severe). Eleven main
symptoms were analyzed: breathing problems,
nasal irritation, throat irritation, hoarseness,
chest pain/pressure, phlegm, eye irritation,
dizziness, headache, fatigue, and sweating. The
selection of symptoms was based on previous
experience (Ternesten-Hasseus et al. 2002b). 
Collection of NAL and determination of
nerve growth factor. A 5-mL aliquot of room-
tempered saline was instilled into the right nos-
tril of the subjects before and directly after
capsaicin provocation. The subject’s head was
tilted back and after approximately 10 sec the
head was raised and NAL expelled into a col-
lecting basin, measured for volume, and then
transferred into conical tubes. We measured
the returned volume and centrifuged it at 400g
for 10 min at 4°C. The supernatant was then
frozen at –80°C. We measured concentrations
of NGF in supernatant samples of pre- and
postcapsaicin challenge NAL using an enzyme-
linked immunosorbent assay (ELISA; Duo Set
ELISA; R&D Systems, Abingdon, UK). Nerve
growth factor in standard and samples was
bound to an anti-NGF mouse monoclonal
antibody coated onto a BD Falcon 96-well
microplate (BD Biosciences, Bedford, MA,
USA). After washing, we added biotinylated
goat antihuman NGF and allowed it to bind to
the NGF. After another wash, we added perox-
idase-labeled streptavidin and allowed it to
bind to the biotin on the goat antibodies. After
a ﬁnal wash, tetramethylbenzidine was added
as an enzyme substrate. We added sulfuric acid
as a stop solution and determined the amount
of NGF by optical density using a microplate
reader set at 450 nm (VMax microplate reader;
Molecular Devices, Sunnyvale, CA, USA). We
used recombinant human NGF as standard,
ranging from 15.6 to 2,000 ng/L. The assay
had a lower detection limit of 2 pg/mL. To test
the speciﬁcity of the assay, we performed dou-
ble ELISA measurements of NGF on each
specimen.
Statistics. We analyzed the results obtained
with different doses in the two groups using
the Mann-Whitney U-test for nonpaired data
and the Wilcoxon signed-rank test for paired
data. Data are presented as means and 95%
confidence intervals (CIs), and a p-value of
< 0.05 was taken as statistically signiﬁcant.
Results
Outcome of the capsaicin provocations. Both
patient and control groups demonstrated a
dose-dependent response to capsaicin inhala-
tion. In the patient group, the mean number
of coughs was 21 (95% CI, 0–44), 58 (95%
CI, 34–73) and 86 (95% CI, 74–98) for the
three doses, respectively. The corresponding
values for the control group were 6 (95% CI,
0–13), 17 (95% CI, 12–23), and 37 (95%
CI, 26–48). With each dose of capsaicin, the
patient group coughed significantly more
than the control group (p < 0.01 for the
0.4 µM dose and p < 0.001 for both 2 and
10 µM doses). 
In addition to increased coughing in
patients, capsaicin provocations induced other
symptoms, the most common being throat
irritation, heavy breathing, eye irritation,
phlegm, and rhinorrohea. The control subjects
had no, or only a few, symptoms induced by
capsaicin inhalation. The mean FEV1 in the
patient group was 99% (95% CI, 90–108) of
that predicted before capsaicin inhalation
provocations, and no significant differences
were found after the provocations.
Nerve growth factor in NAL. The double
ELISA measurements of NGF, performed on
each specimen, were constant, without signiﬁ-
cant differences in the outcome of the results
from capsaicin provocations. Basal levels of
NGF were significantly lower (p < 0.02) in
the patient group: their mean value was
13.8 pg/mL (95% CI, 6.3–21.4) compared
with control subjects, who had mean values
of 25.1 pg/mL (95% CI, 18.9–31.2). After
capsaicin inhalation, there was an increase in
NGF in the patient group (mean increase after
provocation: 11.1 pg/mL; 95% CI, 3.1–19.1;
p < 0.01) but not among control subjects, who
displayed a decrease in NGF (mean decrease
after provocation: 3.2 pg/mL; 95% CI, –1.6
to 8.1). The change in NGF levels after cap-
saicin provocation differed significantly
between the two groups (p < 0.005; Figure 1). 
In the patient group, there was a statisti-
cally signiﬁcant correlation between the num-
ber of coughs after the highest inhaled
capsaicin dose (10 µM) and the change in
NGF levels in NAL after provocation
(p < 0.01, r = 0.7; Figure 2). After the highest
inhaled capsaicin concentration, each of the
symptom scores for throat irritation, phlegm,
and rhinorrohea correlated significantly
(p < 0.004, r = 0.8; p < 0.04, r = 0.6; and
p < 0.04, r = 0.8, respectively) with the change
in NGF levels in NAL after provocation. 
Discussion
The main ﬁnding of this study is that patients
with SHR do have enhanced cough sensitivity
to inhaled capsaicin, which correlates to a small
but signiﬁcant increase in NGF in NAL after
capsaicin provocation. This indicates a neuro-
chemical imbalance of the respiratory system in
patients with SHR. Because there are similari-
ties in symptoms and capsaicin sensitivity
between patients with SHR and patients with
MCS (Ternesten-Hasseus et al. 2002a), the
groups probably overlap each other.
Compared with patients with asthma and
allergy, the levels and increase of NGF are dis-
crete and emphasize the discrepancy between
these two conditions, though these groups
have similar airway symptoms and are often
confused. Recent studies have shown an inter-
play between NGF and airway inﬂammation.
Millqvist et al.




















Figure 1. Box plot of NGF levels in 13 patients with
airway symptoms induced by scents and chemicals
and 14 control subjects before and after inhalation
provocation with three concentrations of capsaicin.
See “Materials and Methods” for details. The hori-
zontal line in the center of each box is the median.
The top and bottom of the box represent the 25th
and 75th percentiles, and whiskers indicate the 10th
and 90th percentiles. Circles are individual maximum
and minimum data points.Increased levels of NGF have been found in
the serum, bronchial tissue, and broncho-
alveolar fluid of patients with allergy and
asthma (Bonini et al. 1996; Noga et al. 2001,
2003; Olgart Hoglund et al. 2002). In
patients with allergic rhinitis, levels of NGF
in NAL were increased after allergen provoca-
tion compared with control subjects (Sanico
et al. 2000). 
Among the patients in our study, the
lower basal NGF levels in NAL may seem sur-
prising, but this finding underlines that
patients with SHR do not have mucosal
inflammation, which is probably the main
source of high airway NGF levels in asthma
and allergy sufferers. However, in this study,
the NGF reaction induced by capsaicin was
evident among patients and may be derived
from hyperreactive nerve endings. The ner-
vous system of patients with SHR may have
an ability to overrespond to noxious stimuli
with NGF production, which, in the long run,
is followed by depletion of basal neurotrophin
levels. Because the original source of NGF is
unknown, one possibility is that the measured
levels of NGF reﬂect plasma levels or levels in
the lower airways. In control subjects, levels of
NGF were unchanged, with a tendency
toward lower values after capsaicin provoca-
tion. This indicates a stable system in the con-
trol group, where, after two nasal lavages,
some of the NGF had been rinsed out. 
After capsaicin challenge, the symptom
scores for rhinitis had a strong, but unsurpris-
ing, correlation with an increase in NGF,
because the nasal mucosa may have produced
the factor being analyzed. However, the
mechanisms behind the reaction are unclear:
it could be reﬂex mediated; a small amount of
capsaicin could have reached the nose from
the pharynx; or some of the nebulized solu-
tion could have been dispersed and inhaled
through the nose because the patients did not
use a nose clip. 
The NAL technique involves dilution of
the expelled nasal secretions. We did not esti-
mate the dilution factor, which is a possible
source of error in the measured NGF. Most
patients complained of rhinorrohea after cap-
saicin provocation, which may have con-
tributed to a further dilution of NAL in
patient group compared to controls. However,
after provocation, there was an increase in
NGF per milliliter of NAL and also a correla-
tion with a high rhinorrohea score in the
patient group; therefore, the dilution effect
should not invalidate the results. Because of
the dilution of NAL, the absolute NGF values
must be regarded as uncertain and conclusions
could be drawn only from group levels. In
future research, albumin levels should also be
measured to compensate for the dilutional
effect. Another source of error for measured
NGF may have been the inﬂuence of medica-
tion in the patient group. Five of the patients
were on regular medication with β2 agonists
or inhaled steroids, both of which are known
to suppress NGF production (Amann and
Schuligoi 2004; Noga et al. 2001). 
Previously, an abnormality of the sensory
nervous system in the airways was suggested in
the pathophysiology of patients with symp-
toms induced by chemicals (Meggs 1995).
Recently, Kimata (2004) recorded increased
plasma levels of substance P, vasoactive intesti-
nal peptide, and NGF in patients with self-
reported MCS, which support this theory.
This theory is also corroborated by the ﬁnd-
ings of augmented cough sensitivity to inhaled
capsaicin (Johansson et al. 2002; Millqvist
2000; Millqvist et al. 1998, 2000; Ternesten-
Hasseus et al. 2002b). Increased levels of sub-
stance P were found in NAL of patients with
chronic cough but without bronchial hyper-
responsiveness; there was also increased cap-
saicin cough sensitivity compared with controls
(Cho et al. 2003). The conditions of chronic
cough and airway sensitivity to scents and
chemicals are closely related. Many patients
with SHR complain of daily problems with
cough (Millqvist et al. 1998, 2000; Ternesten-
Hasseus et al. 2002b). However, it is not
known how often patients with a diagnosis of
chronic cough are also intolerant to scents and
chemicals. In both conditions, there is no
well-defined explanation, but neurochemical
ﬁndings allude to analogous mechanisms. 
In animals, NGF acutely conditions the
response to capsaicin, suggesting that NGF
may be important in sensitizing the response
of sensory neurons and may play a role in pain
and hyperalgesia (Anand 1995, 2004; Shu and
Mendell 1999b, 2001). Initial interpretation
of the findings in the present study suggests
that an alteration of neurochemical balance in
the airways is related to SHR, resulting in
cough and other airway symptoms. We
hypothesize that a type of mucosal hyperalge-
sia has occurred in patients with SHR. The
upper and lower airways could mirror each
other by trigeminal and vagal reflexes—the
two main sensory nerves of the airways.
Neuropeptides released from the lower airways
may also induce symptoms in the other end of
the airway system and vice versa. The term
“united airways” is often used with reference
to asthma and allergy, but it is probably, more
or less, suited to most conditions in the air-
ways. A sensory hyperreactivity after contact
with chemical stimuli, in concentrations nor-
mally regarded as harmless, may result in
symptoms mimicking those usually elicited by
noxious stimuli and resulting in symptoms in
both the upper and the lower airways. Other
neurochemical factors, such as neuropeptides,
will need to be analyzed in the future. 
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